| Not Yet Recruiting | NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-II Breast Cancer, Triple-negative Breast Cancer | Phase 3 | 2026-01-31 |
| Not Yet Recruiting | Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/ Breast Cancer, HR+/HER2- Breast Cancer | Phase 3 | 2026-01-31 |
| Recruiting | Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Stan Breast Cancer, HR-positive Breast Cancer, Advanced Breast Cancer | Phase 3 | 2025-11-27 |
| Recruiting | NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT- Triple Negative Breast Cancer | Phase 3 | 2024-10-10 |
| Active Not Recruiting | NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Brea HER2-positive Early Breast Cancer | Phase 2 | 2024-02-05 |
| Recruiting | PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS Female Breast Cancer | — | 2022-12-07 |
| Active Not Recruiting | Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC Breast Cancer Female | Phase 3 | 2020-09-02 |
| Completed | A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Earl Breast Cancer | Phase 2 | 2020-08-18 |
| Active Not Recruiting | Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HE Breast Cancer Female | Phase 3 | 2019-07-02 |
| Completed | PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2- Breast Cancer | — | 2015-04-01 |
| Completed | A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Early Primary Breast Cancer | Phase 3 | 2014-07-01 |
| Completed | A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pe Breast Cancer | Phase 2 | 2014-03-01 |
| Terminated | Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Brea Carcinoma, Ductal, Breast | Phase 2 | 2013-09-30 |
| Completed | Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Pr Breast Cancer | Phase 2 | 2013-06-01 |
| Completed | A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) Wit Breast Cancer | Phase 2 | 2012-11-01 |
| Terminated | Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON) Breast Cancer | Phase 2 | 2012-09-01 |
| Completed | ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Res Breast Cancer | Phase 2 / Phase 3 | 2012-05-01 |
| Completed | Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Pr Breast Cancer | Phase 2 / Phase 3 | 2012-05-01 |
| Completed | Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer Primary Breast Cancer, Her2 Non-overexpressing | Phase 3 | 2009-02-05 |
| Completed | 4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF Breast Cancer | Phase 3 | 2000-06-01 |